Positive memory training for the treatment of depression in schizophrenia: A randomised controlled trial

<p><strong>Background:</strong><br /> Around half of people diagnosed with schizophrenia suffer from co-morbid depression, yet there are no evidence-based psychological treatments to target this presentation.</p><br /> <p><strong>Method:</strong>...

Full description

Bibliographic Details
Main Authors: Steel, C, Korrelboom, K, Fazil Baksh, M, Kingdon, D, Simon, J, Wykes, T, Phiri, P, van der Gaag, M
Format: Journal article
Language:English
Published: Elsevier 2020
_version_ 1797107748118200320
author Steel, C
Korrelboom, K
Fazil Baksh, M
Kingdon, D
Simon, J
Wykes, T
Phiri, P
van der Gaag, M
author_facet Steel, C
Korrelboom, K
Fazil Baksh, M
Kingdon, D
Simon, J
Wykes, T
Phiri, P
van der Gaag, M
author_sort Steel, C
collection OXFORD
description <p><strong>Background:</strong><br /> Around half of people diagnosed with schizophrenia suffer from co-morbid depression, yet there are no evidence-based psychological treatments to target this presentation.</p><br /> <p><strong>Method:</strong><br /> Participants were aged 18–65 years old, had a clinical diagnosis of schizophrenia or schizoaffective disorder and at least a mild level of depression. Participants were randomly assigned (1:1) to receive PoMeT or treatment as usual. PoMeT was delivered in up to 12 individual sessions within 3 months. We stratified randomisation by site and by severity of depression using randomised-permuted blocks. Assessments were carried out at baseline, 3-month, 6-month and 9-month by assessors who were blind to treatment allocation. The primary outcome was reduction in the symptoms of depression at 3-month, 6-month and 9-month as measured by the BDI-II. Analysis was by intention-to-treat with linear mixed-effects models. The trial was registered with the ISRCTN registry number 99485756.</p><br /> <p><strong>Results:</strong><br /> One hundred participants were randomly assigned to either PoMeT (n = 49) or treatment as usual (n = 51). The reduction in BDI-II total score at 3 months was significantly greater for PoMeT than for treatment as usual (mean difference = 4.33, SE = 2.00, 95% CI 0.38 to 8.23; p = 0.03).</p><br /> <p><strong>Discussion:</strong><br /> To our knowledge this is, to date, the largest powered randomised controlled trial focused on the psychological treatment of depression in people diagnosed with schizophrenia. Results indicate that a brief targeted intervention can reduce the symptoms of depression in the group. The main limitation of the study is the lack of an active control group which may contribute to an inflated treatment effect.</p>
first_indexed 2024-03-07T07:20:22Z
format Journal article
id oxford-uuid:cc86a9d7-13bd-4e2e-ba91-4927ff1c4ba9
institution University of Oxford
language English
last_indexed 2024-03-07T07:20:22Z
publishDate 2020
publisher Elsevier
record_format dspace
spelling oxford-uuid:cc86a9d7-13bd-4e2e-ba91-4927ff1c4ba92022-09-22T07:46:57ZPositive memory training for the treatment of depression in schizophrenia: A randomised controlled trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:cc86a9d7-13bd-4e2e-ba91-4927ff1c4ba9EnglishSymplectic ElementsElsevier2020Steel, CKorrelboom, KFazil Baksh, MKingdon, DSimon, JWykes, TPhiri, Pvan der Gaag, M<p><strong>Background:</strong><br /> Around half of people diagnosed with schizophrenia suffer from co-morbid depression, yet there are no evidence-based psychological treatments to target this presentation.</p><br /> <p><strong>Method:</strong><br /> Participants were aged 18–65 years old, had a clinical diagnosis of schizophrenia or schizoaffective disorder and at least a mild level of depression. Participants were randomly assigned (1:1) to receive PoMeT or treatment as usual. PoMeT was delivered in up to 12 individual sessions within 3 months. We stratified randomisation by site and by severity of depression using randomised-permuted blocks. Assessments were carried out at baseline, 3-month, 6-month and 9-month by assessors who were blind to treatment allocation. The primary outcome was reduction in the symptoms of depression at 3-month, 6-month and 9-month as measured by the BDI-II. Analysis was by intention-to-treat with linear mixed-effects models. The trial was registered with the ISRCTN registry number 99485756.</p><br /> <p><strong>Results:</strong><br /> One hundred participants were randomly assigned to either PoMeT (n = 49) or treatment as usual (n = 51). The reduction in BDI-II total score at 3 months was significantly greater for PoMeT than for treatment as usual (mean difference = 4.33, SE = 2.00, 95% CI 0.38 to 8.23; p = 0.03).</p><br /> <p><strong>Discussion:</strong><br /> To our knowledge this is, to date, the largest powered randomised controlled trial focused on the psychological treatment of depression in people diagnosed with schizophrenia. Results indicate that a brief targeted intervention can reduce the symptoms of depression in the group. The main limitation of the study is the lack of an active control group which may contribute to an inflated treatment effect.</p>
spellingShingle Steel, C
Korrelboom, K
Fazil Baksh, M
Kingdon, D
Simon, J
Wykes, T
Phiri, P
van der Gaag, M
Positive memory training for the treatment of depression in schizophrenia: A randomised controlled trial
title Positive memory training for the treatment of depression in schizophrenia: A randomised controlled trial
title_full Positive memory training for the treatment of depression in schizophrenia: A randomised controlled trial
title_fullStr Positive memory training for the treatment of depression in schizophrenia: A randomised controlled trial
title_full_unstemmed Positive memory training for the treatment of depression in schizophrenia: A randomised controlled trial
title_short Positive memory training for the treatment of depression in schizophrenia: A randomised controlled trial
title_sort positive memory training for the treatment of depression in schizophrenia a randomised controlled trial
work_keys_str_mv AT steelc positivememorytrainingforthetreatmentofdepressioninschizophreniaarandomisedcontrolledtrial
AT korrelboomk positivememorytrainingforthetreatmentofdepressioninschizophreniaarandomisedcontrolledtrial
AT fazilbakshm positivememorytrainingforthetreatmentofdepressioninschizophreniaarandomisedcontrolledtrial
AT kingdond positivememorytrainingforthetreatmentofdepressioninschizophreniaarandomisedcontrolledtrial
AT simonj positivememorytrainingforthetreatmentofdepressioninschizophreniaarandomisedcontrolledtrial
AT wykest positivememorytrainingforthetreatmentofdepressioninschizophreniaarandomisedcontrolledtrial
AT phirip positivememorytrainingforthetreatmentofdepressioninschizophreniaarandomisedcontrolledtrial
AT vandergaagm positivememorytrainingforthetreatmentofdepressioninschizophreniaarandomisedcontrolledtrial